{"id":53328,"date":"2025-09-19T06:39:03","date_gmt":"2025-09-19T10:39:03","guid":{"rendered":"https:\/\/stockmarketwatch.com\/stock-market-news\/global-markets-react-to-central-bank-shifts-key-pharma-approvals-and-german-energy-strategy\/53328\/"},"modified":"2025-09-19T06:39:03","modified_gmt":"2025-09-19T10:39:03","slug":"global-markets-react-to-central-bank-shifts-key-pharma-approvals-and-german-energy-strategy","status":"publish","type":"post","link":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/global-markets-react-to-central-bank-shifts-key-pharma-approvals-and-german-energy-strategy\/53328\/","title":{"rendered":"Global Markets React to Central Bank Shifts, Key Pharma Approvals, and German Energy Strategy"},"content":{"rendered":"<h2>Key Takeaways<\/h2>\n<ul>\n<li>The <strong>Bank of Japan<\/strong> (<a href=\"\/currency\/JPY\">JPY<\/a>) maintained its benchmark interest rate at <strong>0.50%<\/strong> but surprised markets by announcing the sale of its <strong>ETF and J-REIT holdings<\/strong>, signaling a move towards policy normalization and causing the <strong>Japanese Yen<\/strong> to strengthen.<\/li>\n<li>The <strong>European Union<\/strong> approved significant new therapy options, including <strong>Merck&#39;s<\/strong> (<a href=\"\/stock\/MRK\">MRK<\/a>) <strong>Enflonsia<\/strong> for RSV prevention in infants and an extended label for <strong>Novo Nordisk&#39;s<\/strong> (<a href=\"\/stock\/NVO\">NVO<\/a>) oral semaglutide (<strong>Rybelsus<\/strong>) for cardiovascular benefits in type 2 diabetes.<\/li>\n<li><strong>Germany&#39;s Economy Ministry<\/strong> is actively exploring options for nationalized energy firms <strong>SEFE<\/strong> and <strong>Uniper<\/strong>, including a potential sale, IPO, or even a merger to create a &quot;German gas giant,&quot; driven by an <strong>EU mandate<\/strong> to reduce state ownership by <strong>2028<\/strong>.<\/li>\n<li><strong>Citigroup<\/strong> (<a href=\"\/stock\/C\">C<\/a>) made notable analyst calls, downgrading <strong>Intel<\/strong> (<a href=\"\/stock\/INTC\">INTC<\/a>) to &quot;Sell&quot; despite raising its price target to <strong>$29<\/strong> following <strong>Nvidia&#39;s<\/strong> (<a href=\"\/stock\/NVDA\">NVDA<\/a>) <strong>$5 billion investment<\/strong>, while also increasing its target price for <strong>Bank of America<\/strong> (<a href=\"\/stock\/BAC\">BAC<\/a>) to <strong>$58<\/strong>.<\/li>\n<li><strong>AstraZeneca&#39;s<\/strong> (<a href=\"\/stock\/AZN\">AZN<\/a>) <strong>Koselugo<\/strong> received <strong>EU approval<\/strong> for extended use in adult and pediatric patients with neurofibromatosis type 1 (NF1), expanding its therapeutic reach.<\/li>\n<\/ul>\n<h2>Central Banks and Currency Markets in Focus<\/h2>\n<p>The <strong>Bank of Japan (BoJ)<\/strong> maintained its benchmark short-term interest rate at <strong>0.50%<\/strong> following a 7-2 vote, aligning with market expectations. However, the central bank surprised investors by announcing it would begin selling its holdings of exchange-traded funds (ETFs) and Japan Real Estate Investment Trusts (J-REITs) at an annual pace of approximately <strong>JPY 330 billion<\/strong> and <strong>JPY 5 billion<\/strong>, respectively. This unexpected move, seen as a &quot;hawkish twist,&quot; led to a notable strengthening of the <strong>Japanese Yen<\/strong> (<a href=\"\/currency\/JPY\">JPY<\/a>) against the <strong>US Dollar<\/strong> (<a href=\"\/currency\/USD\">USD<\/a>).<\/p>\n<p>Meanwhile, <strong>US equity futures<\/strong> remained flat, and <strong>European bourses<\/strong> were mostly higher as markets absorbed the BoJ&#39;s decision and looked ahead to a scheduled call between <strong>US President Trump<\/strong> and <strong>Chinese President Xi Jinping<\/strong>. Discussions during the call are anticipated to cover the future of TikTok&#39;s US operations and broader trade relations, potentially influencing risk assets.<\/p>\n<h2>Pharmaceutical Sector Sees Key European Approvals<\/h2>\n<p>The European Union&#39;s pharmaceutical landscape is experiencing significant developments with multiple new drug approvals. <strong>Merck&#39;s<\/strong> (<a href=\"\/stock\/MRK\">MRK<\/a>) <strong>Enflonsia<\/strong> (clesrovimab) received a positive recommendation for marketing authorization from the <strong>European Medicines Agency&#39;s (EMA) Committee for Medicinal Products for Human Use (CHMP)<\/strong> on September 18, 2025. This approval is for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. Enflonsia stands out as the first RSV preventive for infants to offer a single, fixed <strong>105 mg dose<\/strong> regardless of the child&#39;s weight, a key differentiator from existing treatments. This follows its earlier FDA approval in June 2025.<\/p>\n<p>In another significant development, <strong>Novo Nordisk&#39;s<\/strong> (<a href=\"\/stock\/NVO\">NVO<\/a>) oral semaglutide, marketed as <strong>Rybelsus<\/strong>, received <strong>EU approval<\/strong> for an updated label. The update reflects proven cardiovascular benefits for patients with type 2 diabetes, making it the first and only oral GLP-1 RA to demonstrate a reduction in cardiovascular death, heart attack, and stroke. This approval is based on positive data from the SOUL trial.<\/p>\n<p>Additionally, <strong>AstraZeneca\u2019s<\/strong> (<a href=\"\/stock\/AZN\">AZN<\/a>) <strong>Koselugo<\/strong> (selumetinib) has been approved in Europe for extended use. The <strong>EMA&#39;s CHMP<\/strong> recommended a change to its marketing authorization to include adult and pediatric patients aged 3 years and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). This expansion follows successful results from the Phase III KOMET trial, which demonstrated a statistically significant and clinically meaningful objective response rate in adult patients.<\/p>\n<h2>German Government Explores Options for Nationalized Energy Firms<\/h2>\n<p>The <strong>German Economy Ministry<\/strong> has announced it is exploring various strategic options for the nationalized energy companies <strong>SEFE<\/strong> (Securing Energy for Europe) and <strong>Uniper<\/strong>. These options include a potential sale, an initial public offering (IPO), or even a merger of the two entities to form a &quot;German gas giant.&quot; The deliberations are driven by an <strong>EU mandate<\/strong> requiring Berlin to reduce its stake in both companies to no more than <strong>25% plus one share by 2028<\/strong>.<\/p>\n<p>Both <strong>SEFE<\/strong> and <strong>Uniper<\/strong> were nationalized in 2022 to ensure energy supply security during Europe&#39;s energy crisis, with <strong>SEFE<\/strong> receiving a <strong>\u20ac6.3 billion<\/strong> bailout and <strong>Uniper<\/strong> a <strong>\u20ac13.5 billion<\/strong> government injection. While the economy ministry is reportedly open to a tie-up, the finance ministry remains more skeptical, viewing a merger as a fallback if independent sales fail.<\/p>\n<h2>Analyst Ratings and M&amp;A Activity<\/h2>\n<p><strong>Citigroup<\/strong> (<a href=\"\/stock\/C\">C<\/a>) issued a notable downgrade for <strong>Intel<\/strong> (<a href=\"\/stock\/INTC\">INTC<\/a>), moving it to &quot;Sell&quot; from &quot;Neutral,&quot; despite simultaneously increasing its price target to <strong>$29 from $24<\/strong>. This decision follows a recent rally in Intel shares, spurred by <strong>Nvidia&#39;s<\/strong> (<a href=\"\/stock\/NVDA\">NVDA<\/a>) announced <strong>$5 billion investment<\/strong> and collaboration to jointly develop datacenter and PC chips. Citi analysts expressed skepticism regarding the deal&#39;s ability to significantly boost Intel&#39;s struggling foundry business. In a separate move, <strong>Citigroup<\/strong> also raised its price target on <strong>Bank of America<\/strong> (<a href=\"\/stock\/BAC\">BAC<\/a>) to <strong>$58 from $54<\/strong>, while maintaining a &quot;Buy&quot; rating.<\/p>\n<p>In the private equity space, the <strong>European Commission<\/strong> has approved <strong>Warburg Pincus&#39;s<\/strong> acquisition of a majority stake in <strong>Uvex Group<\/strong>. The transaction, announced on July 1, 2025, sees the US-based global private equity fund taking control of the German protective safety and sports equipment company in a deal reportedly valued at approximately <strong>\u20ac800 million<\/strong>. The founding Winter and Grau families will retain a significant minority stake in the business.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Key Takeaways The Bank of Japan (JPY) maintained its benchmark interest rate at 0.50% but surprised markets by announcing the [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":50383,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"rank_math_schema_Article":[],"rank_math_focus_keyword":[],"rank_math_description":[],"financial_data_references":[],"stock_symbols_mentioned":[],"footnotes":""},"categories":[5012],"tags":[11055,4395,5775,31,11056,4945,6253,647,11057,6334,1067,11058,5030,6371,2004,5072,6634,3591,5081,6765,3744,5134,10440,3774,5377,11052,3829,5383,11053,3906,5515,11054,4147,5556],"class_list":["post-53328","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-breaking-news","tag-koselugo","tag-equity-markets","tag-pharmaceuticals","tag-intc","tag-rybelsus","tag-monetary-policy","tag-astrazeneca","tag-azn","tag-enflonsia","tag-novo-nordisk","tag-mrk","tag-pn","tag-energy","tag-rsv","tag-usd","tag-germany","tag-intel","tag-forex","tag-jpy","tag-chmp","tag-nvo","tag-central-banks","tag-sefe","tag-c","tag-bank-of-japan","tag-warburg-pincus","tag-ma","tag-biotech","tag-uvex-group","tag-ema","tag-citigroup","tag-uniper","tag-ipo","tag-merck"],"_links":{"self":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/53328","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/comments?post=53328"}],"version-history":[{"count":0,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/53328\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media\/50383"}],"wp:attachment":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media?parent=53328"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/categories?post=53328"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/tags?post=53328"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}